Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition
New treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are key mediators to promote growth of PC. Here, we evaluate the potential of immunopr...
Saved in:
| Main Authors: | Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2156091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting AURKA with multifunctional nanoparticles in CRPC therapy
by: Bin Deng, et al.
Published: (2024-12-01) -
A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
by: Xiannan Meng, et al.
Published: (2025-01-01) -
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
by: Jaeyoung Cho, et al.
Published: (2023-11-01) -
Nomogram Analysis for Predicting Response to Androgen‐Receptor‐Axis‐Targeted Therapies in Patients With Metastatic Castration‐Resistant Prostate Cancer
by: I‐Hung Shao, et al.
Published: (2024-11-01) -
Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)